Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:53:14.687Z.
Calculation as of: 2026-10-06T19:53:14.687Z.
Quote observation: 2026-10-06T19:50:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$439.45M
EV/FCF Ratio
N/A
TTM Avg
2.71x
3Y Avg
2.71x
5Y Avg
2.71x
Market Cap
$455.45M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$446.76M
EV/FCF Ratio
N/A
TTM Avg
0.21x
3Y Avg
0.21x
5Y Avg
0.21x
Market Cap
$422.54M
EV/FCF Ratio
N/A
TTM Avg
98.46x
3Y Avg
98.46x
5Y Avg
98.46x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $435.38M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.45M | N/A | 2.71x | 2.71x | 2.71x |
| YD Bio Limited Ordinary Shares (YDES)vs › | $455.45M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $427.95M | N/A | 51.06x | 46.23x | 33.62x |
| Ovid Therapeutics Inc. (OVID)vs › | $446.76M | N/A | 0.21x | 0.21x | 0.21x |
| Tilray Brands, Inc. (TLRY)vs › | $423.28M | N/A | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $423.00M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.54M | N/A | 98.46x | 98.46x | 98.46x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | N/A | 25.38x | 25.38x | 25.38x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
